A NEW “game-changing” drug could stop the progression of Alzheimer’s disease, early trials suggest. Scientists say the ...

In a Phase Ib/IIa trial, 91% of patients receiving the highest dose of trontinemab were amyloid negative after seven months ...

Trontinemab is one of a class of new medicines aimed at clearing amyloid plaques. The new findings from phase two trials ...

Swiss pharmaceutical giant Roche is set to explore the potential of its experimental drug, Trontinemab, in delaying or ...

Swiss drugmaker Roche Holding plans to investigate whether an experimental medicine can delay or prevent Alzheimer’s disease ...

A new Alzheimer’s drug has been hailed as a major breakthrough after clinical trials showed it could clear the harmful brain ...

Swiss pharma major Roche (ROG: SIX) has outlined ambitious plans to accelerate the development of trontinemab, its ...

Trontinemab’s Phase Ib/IIa Brainshuttle™ AD study continues to show rapid and robust clearance of amyloid plaques, with 91% ...

TORONTO -- An investigational antibody drug, designed to cross the blood-brain barrier (BBB) to eliminate amyloid-beta ...

Roche has added another phase 3 trial in its programme for Alzheimer's disease candidate trontinemab and will now test the ...